Johnson & Johnson vs Rivian Automotive, Inc. — how do they compare? Johnson & Johnson trades at $260.51 (market cap $626.09B), while Rivian Automotive, Inc. trades at $15.96 (market cap $23.69B). The key difference: Johnson & Johnson is far larger — about 26.4× Rivian Automotive, Inc.'s market cap, and Johnson & Johnson pays a 2.06% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| JNJ | RIVN | |
|---|---|---|
Market Cap | $626.09B | $23.69B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $22.45 |
52-Week Low | $172.78 | $11.97 |
Enterprise Value | $654.37B | $23.73B |
Dividend Yield | 2.06% | — |
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $260.88, down 0.36% today, with a bullish technical signal supported by moving averages. The stock shows strong profitability with a net margin of 21.48% and ROE of 25.74%, though valuations like a P/E of 30.14 appear elevated. Recent earnings beat expectations in Q1 and Q2 2026, and the company maintains a 64-year dividend growth streak, with analyst consensus leaning bullish.
Outlook remains positive with a consensus price target of $284.50, offering potential upside, but risks include legal challenges and high debt-to-asset ratio of 24.06% in 2025. Investors benefit from steady dividends and defensive positioning in healthcare, though valuation multiples may limit near-term gains amid economic uncertainty.
Rivian (RIVN) trades at $16.015, down 2.29% today, with a bullish technical signal from moving averages but neutral oscillators. The company shows improving fundamentals with revenue growth from $5.0B in 2024 to $5.4B in 2025, though net losses persist at -$3.65B. Recent R2 vehicle launches and raised 2026 delivery guidance to 65,000-70,000 vehicles indicate operational progress. Analyst consensus is mixed with 48% buy ratings and a $18.70 price target, suggesting 17% upside potential from current levels.
Rivian presents a high-risk growth opportunity with significant cash burn ($1.72B net outflow in 2025) but improving margin trends. The R2 ramp-up and Uber partnership offer catalysts, though execution risks and EV market competition remain concerns. With negative profitability metrics and substantial debt, the stock suits investors comfortable with early-stage company volatility seeking EV market exposure.
Trailing returns across standard periods
Latest headlines on both assets
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →